Lupin Q2 FY27: revenue up 11.1% to ₹7,827 Cr, net profit down 21.8% to ₹1,155 Cr
Results · Finvezto · 4 Nov 2026 · Lupin (LUPIN)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 7,827 | - | +11.1% |
| Operating profit | 2,171 | - | - |
| Net profit | 1,155 | - | -21.8% |
| Operating margin | 27.7% | - | - |
| Net margin | 14.8% | - | -6.2 pp |
YoY is the company's own figure. QoQ shows where our quarterly series matches the filing.
Key points
- For Q2 FY2027, Lupin Limited reported consolidated sales of Rs 7,785.5 crore, up 14.0% year-on-year from Rs 6,831.4 crore, while EBITDA declined 10.7% to Rs 2,171.2 crore and profit after tax fell 22.2% to Rs 1,155.3 crore. NSE filing
- Revenue was driven by 9.3% growth in U.S. sales to Rs 3,020.2 crore and a 14.7% rise in India sales to Rs 2,383.6 crore, while gross margin expanded to 74.2%. NSE filing
- Total revenues from operations for Q2 FY27 grew 11% year-on-year to INR 7,827 crores, driven by double-digit organic growth across India and Other Developed Markets. Earnings call
- India formulations revenue grew 14.7% year-on-year, led by diabetes expanding over 25% and the chronic segment growing 19.5% to reach 66% of the portfolio. Earnings call
What to watch
- Management on fy27 ebitda margin: We remain committed to our FY27 margin guidance of around 24-25%, while recognizing that margins are likely to moderate in the coming quarters.
- Management on fy27 u.s. revenues: For FY27, we continue to expect U.S. revenues in the range of USD 1.1 billion to USD 1.2 billion.
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.